According to the KEYNOTE-010 trial and the KEYNOTE-042 trial, pembrolizumab revealed better efficacy in advanced NSCLC patients with positive PD-L1 expression than chemotherapy [26, 27]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.